Skip to main content
x

Recent articles

More ROR1s enter the clinic

The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.

Like Crest, Potomac succeeds up to a point

Imfinzi hits on disease-free survival, but BCG won't be displaced.

Ivonescimab takes on pancreatic cancer

Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.

Takeda says no to B7-H3

TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Revolution gets selective

The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.

The month ahead: May’s remaining events

Conference activity picks up, with the big one – ASCO – at the end of the month.